Search

Your search keyword '"Gjerdrum, Lise Mette Rahbek"' showing total 6 results
Start Over Author "Gjerdrum, Lise Mette Rahbek" Publisher american society of hematology
6 results on '"Gjerdrum, Lise Mette Rahbek"'

1. Malignant T cells induce skin barrier defects through cytokine-mediated JAK/STAT signaling in cutaneous T-cell lymphoma

Author

Gluud, Maria, primary, Pallesen, Emil M. H., additional, Buus, Terkild B., additional, Gjerdrum, Lise Mette Rahbek, additional, Lindahl, Lise M., additional, Kamstrup, Maria R., additional, Bzorek, Michael, additional, Danielsen, Maria, additional, Bech, Rikke, additional, Monteiro, Madalena N., additional, Blümel, Edda, additional, Willerslev-Olsen, Andreas, additional, Lykkebo-Valløe, Anders, additional, Vadivel, Chella Krishna, additional, Krejsgaard, Thorbjørn, additional, Bonefeld, Charlotte Menne, additional, Geisler, Carsten, additional, Becker, Jürgen C., additional, Koralov, Sergei B., additional, Iversen, Lars, additional, Litman, Thomas, additional, Woetmann, Anders, additional, and Ødum, Niels, additional

Published
2023
Full Text
View/download PDF

2. Combination Therapy with Ruxolitinib and Interferon in Newly Diagnosed Patients with Polycythemia Vera

Author

Sørensen, Anders Lindholm Lindholm, primary, Skov, Vibe, additional, Kjær, Lasse, additional, Eickhardt-Dalbøge, Christina Schjellerup Schjellerup, additional, Larsen, Morten Kranker, additional, Nielsen, Claus, additional, Thomsen, Carsten, additional, Gjerdrum, Lise Mette Rahbek, additional, Knudsen, Trine Alma, additional, Ellervik, Christina, additional, Overgaard, Ulrik Malthe, additional, Andersen, Christen Lykkegaard, additional, Bjørn, Mads Emil, additional, and Hasselbalch, Hans Carl, additional

Published
2022
Full Text
View/download PDF

3. The Clinical Course and Life Expectancy of Patients with Multiple Myeloma Who Discontinue Their First Daratumumab-Containing Line of Therapy

Author

Szabo, Agoston Gyula, primary, Thorsen, Jonathan, additional, Iversen, Katrine Fladeland, additional, Levring, Mette Bøegh, additional, Preiss, Birgitte, additional, Helleberg, Carsten, additional, Breinholt, Marie Fredslund, additional, Hermansen, Emil, additional, Gjerdrum, Lise Mette Rahbek, additional, Bønløkke, Søren, additional, Nielsen, Katrine, additional, Kjeldsen, Eigil, additional, Teodorescu, Manuela, additional, Dokhi, Marveh, additional, Kurt, Eva, additional, Strandholdt, Casper Noergaard, additional, Andersen, Mette Klarskov, additional, and Vangsted, Annette J., additional

Published
2021
Full Text
View/download PDF

6. Combination Therapy with Ruxolitinib and Pegylated Interferon-alpha2a in Newly Diagnosed Patients with Polycythemia Vera.

Author

Soerensen AL Dr, Skov V, Kjær L, Bjørn ME, Eickhardt-Dalbøge CS, Larsen MK, Nielsen CH, Thomsen C, Gjerdrum LMR, Knudsen TA, Ellervik C, Overgaard UM, Andersen CL, and Hasselbalch HC

Abstract

We report the two-year end-of-study results from the phase 2 COMBI II clinical trial (#EudraCT2018-004150-13) investigating the combination treatment of ruxolitinib and low-dose pegylated interferon-α2a in patients with newly diagnosed polycythemia vera. The primary outcome was safety and key secondary endpoints were efficacy, based on hematological parameters, quality of life measurements, and JAK2V617F variant allele frequency (VAF). We used the 2013 ELN and IWG-MRT remission criteria. The remission criteria included remissions in symptoms, splenomegaly, peripheral blood counts, and bone marrow. We included 25 patients with PV with a median age of 70 years; 5 of those had prior thromboembolic events and three had CT-verified splenomegaly. Two patients stopped both study drugs, one of these due to progression to post-PV myelofibrosis; only that patient had a grade 3 infection. No events of herpes zoster infections were observed. No patients discontinued treatment due to psychiatric symptoms. The peripheral blood cell count remission rate was 92% at 24 months. Using the 2013 ELN and IWG-MRT remission criteria, 14 (56%) achieved remission at 24 months; 3 (12%) achieved complete remission, and 11 (44%) achieved partial remission. The following items from the Myeloproliferative Neoplasm Symptom Total Symptom Score were significantly reduced: abdominal discomfort, night sweats, itching, and bone pain. The median JAK2V617F VAF decreased from 47% (95%CI, 35-59%) to 7% (95%CI, 3-15%), and 60% of patients achieved molecular remission. In conclusion, combination treatment improved cell counts; bone marrow cellularity, and fibrosis; and decreased JAK2V617F VAF; with acceptable toxicity in patients with polycythemia vera. EudraCT2018-004150-13., (Copyright © 2024 American Society of Hematology.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results